These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 38156046)

  • 1. Durability of the Efficacy and Safety of Dolutegravir-Based and Low-Dose Efavirenz-Based Regimens for the Initial Treatment of Human Immunodeficiency Virus Type 1 Infection in Cameroon: Week 192 Data of the NAMSAL-ANRS-12313 Study.
    Mpoudi-Etame M; Tovar Sanchez T; Bousmah MA; Omgba Bassega P; Olinga J; Mimbe E; Foalem M; Chiep C; Edimo S; Varloteaux M; Pelloquin R; Lamare N; Boyer S; Peeters M; Reynes J; Calmy A; Hill A; Delaporte E; Kouanfack C;
    Open Forum Infect Dis; 2023 Dec; 10(12):ofad582. PubMed ID: 38156046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.
    ; Kouanfack C; Mpoudi-Etame M; Omgba Bassega P; Eymard-Duvernay S; Leroy S; Boyer S; Peeters M; Calmy A; Delaporte E
    N Engl J Med; 2019 Aug; 381(9):816-826. PubMed ID: 31339676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improvements in Patient-Reported Outcomes Following Initiation of Dolutegravir-Based or Low-Dose Efavirenz-Based First-Line Antiretroviral Therapy: A Four-Year Longitudinal Analysis in Cameroon (NAMSAL ANRS 12313 Trial).
    Bousmah MA; Protopopescu C; Mpoudi-Etame M; Omgba Bassega P; Maradan G; Olinga J; Varloteaux M; Tovar-Sanchez T; Delaporte É; Kouanfack C; Boyer S;
    J Acquir Immune Defic Syndr; 2023 Nov; 94(3):262-272. PubMed ID: 37851566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection.
    Deng L; Li C; Chen P; Luo X; Zheng X; Zhou L; Zhou Y; Xia J; Hong Z
    BMC Infect Dis; 2022 Jan; 22(1):17. PubMed ID: 34983415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection.
    Walmsley SL; Antela A; Clumeck N; Duiculescu D; Eberhard A; Gutiérrez F; Hocqueloux L; Maggiolo F; Sandkovsky U; Granier C; Pappa K; Wynne B; Min S; Nichols G;
    N Engl J Med; 2013 Nov; 369(19):1807-18. PubMed ID: 24195548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial.
    Osiyemi O; De Wit S; Ajana F; Bisshop F; Portilla J; Routy JP; Wyen C; Ait-Khaled M; Leone P; Pappa KA; Wang R; Wright J; George N; Wynne B; Aboud M; van Wyk J; Smith KY
    Clin Infect Dis; 2022 Sep; 75(6):975-986. PubMed ID: 35079789
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of DTG + ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Med Econ; 2015; 18(10):763-76. PubMed ID: 25934146
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
    Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S;
    Pharmacoeconomics; 2021 Mar; 39(3):331-343. PubMed ID: 33355914
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An indirect comparison of efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir and dolutegravir + abacavir/lamivudine.
    Rogatto F; Bouee S; Jeanbat V; Piontkowsky D; Aragao F; Bosse M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19779. PubMed ID: 25397523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (TDF) Versus Efavirenz/Emtricitabine/TDF in Treatment-naive Adults With Human Immunodeficiency Virus Type 1 Infection: Week 96 Results of the Randomized, Double-blind, Phase 3 DRIVE-AHEAD Noninferiority Trial.
    Orkin C; Squires KE; Molina JM; Sax PE; Sussmann O; Lin G; Kumar S; Hanna GJ; Hwang C; Martin E; Teppler H
    Clin Infect Dis; 2021 Jul; 73(1):33-42. PubMed ID: 33336698
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide-Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study.
    van Wyk J; Ajana F; Bisshop F; De Wit S; Osiyemi O; Portilla Sogorb J; Routy JP; Wyen C; Ait-Khaled M; Nascimento MC; Pappa KA; Wang R; Wright J; Tenorio AR; Wynne B; Aboud M; Gartland MJ; Smith KY
    Clin Infect Dis; 2020 Nov; 71(8):1920-1929. PubMed ID: 31905383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial.
    Llibre JM; Brites C; Cheng CY; Osiyemi O; Galera C; Hocqueloux L; Maggiolo F; Degen O; Taylor S; Blair E; Man C; Wynne B; Oyee J; Underwood M; Curtis L; Bontempo G; van Wyk J
    Clin Infect Dis; 2023 Feb; 76(4):720-729. PubMed ID: 35235656
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-year durable efficacy of dolutegravir plus lamivudine in antiretroviral therapy - naive adults with HIV-1 infection.
    Cahn P; Sierra Madero J; Arribas JR; Antinori A; Ortiz R; Clarke AE; Hung CC; Rockstroh JK; Girard PM; Sievers J; Man CY; Urbaityte R; Brandon DJ; Underwood M; Pappa KA; Curtis L; Smith KY; Gartland M; Aboud M; van Wyk J; Wynne B
    AIDS; 2022 Jan; 36(1):39-48. PubMed ID: 34534138
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world efficacy and safety of dolutegravir plus lamivudine versus tenofovir plus lamivudine and efavirenz in ART-naïve HIV-1-infected adults.
    Li J; Chen D; Wen Z; Du Y; Huang Z; Zhong H; Wang Y; Yin S
    Medicine (Baltimore); 2022 Oct; 101(42):e31100. PubMed ID: 36281149
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Final 192-Week Efficacy and Safety Results of the ADVANCE Trial, Comparing 3 First-line Antiretroviral Regimens.
    Sokhela S; Venter WDF; Bosch B; Woods J; McCann K; Akpomiemie G; Chandiwana N; Mashabane N; Tembo A; Simmons B; Lalla-Edward S; Siedner MJ; Sinxadi P; Hermans L; Fairlie L; Vos A; Abrams E; Manne-Goehler JM; Moorhouse M; Clayden P; Norris S; Qavi A; Chersich M; Masenya M; Arulappan N; Hill A
    Open Forum Infect Dis; 2024 Mar; 11(3):ofae007. PubMed ID: 38529213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of DTG+ABC/3TC versus EFV/TDF/FTC for first-line treatment of HIV-1 in the United States.
    Peng S; Tafazzoli A; Dorman E; Rosenblatt L; Villasis-Keever A; Sorensen S
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19605. PubMed ID: 25394109
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients.
    Punekar YS; Guo N; Tremblay G; Piercy J; Holbrook T; Young B
    Cost Eff Resour Alloc; 2019; 17():26. PubMed ID: 31827410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
    Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
    Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative efficacy and safety and dolutegravir and lamivudine in treatment naive HIV patients.
    Radford M; Parks DC; Ferrante S; Punekar Y
    AIDS; 2019 Sep; 33(11):1739-1749. PubMed ID: 31180906
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor-based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
    Evitt LA; Nanji S; Grove RA; Okoli C; van Wyk J; Snedecor SJ
    AIDS Res Ther; 2023 Mar; 20(1):17. PubMed ID: 36949442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.